Dados do Trabalho

Título

The Real-World Burden of Atopic Dermatitis: MEASURE-AD Multicountry Study Results From Brazil, Mexico, and Argentina

Resumo

Rationale:

The burden of atopic dermatitis (AD), a chronic, relapsing inflammatory skin disease, increases with disease severity and is associated with multiple flares per year over many years. We characterized the real-world burden of disease, including flares, in patients with AD enrolled in MEASURE-AD from Latin America.

Methods:

Patients (aged ≥12 years) with physician confirmed AD receiving or eligible for systemic therapy were enrolled in MEASURE-AD between December 2019 and June 2020. Patient characteristics, treatments, and outcomes were recorded during a single office visit. Primary outcome measures included worst itch within the past 24 hours (Worst Pruritus Numerical Rating Scale [WP-NRS]) and quality of life (QoL; Dermatology Life Quality Index [DLQI] and cDLQI). Among secondary outcomes, frequency and duration of disease flares within the last 6 months were assessed. Herein are results from the Latin American (Brazil, Mexico, Argentina) population (N=180; adults (≥18 years), n=157; adolescents, n=23). Analyses were based on observed data; only descriptive statistics presented.

Results:

Mean (SD) age was 33.8 (17.0) years, 52.2% were males, and all patients were receiving AD treatment, including 65.6% receiving systemic therapy alone or in combination. Severe pruritus (WP-NRS ≥7) was reported by 54.4% of patients (adults, 57.3%; adolescents, 34.8%). A very or extremely large effect on QoL (DLQI or cDLQI ≥11) was reported among 50.0% of patients ≥16 years and 42.9% of patients 12–15 years. Over the previous 6 months, 0, 1‒2, 3‒4, 5‒6, and >6 flares were reported by 8.3%, 27.2%, 31.1%, 11.7%, and 15.6% of patients, respectively. On average, flares lasted 15.2 days (adults, 15.9 days; adolescents, 11.1 days).

Conclusions:

Although all patients received treatment and two-thirds received systemic therapies, severity scores and impact on QoL and itch were extremely high, suggesting that AD is not adequately controlled in all patients.